SYRE - Spyre Therapeutics Inc. logo

Spyre Therapeutics Inc.

SYRE
โš•๏ธ Healthcare NASDAQ Listed 2016 $ USD
$1,000 invested 10 years ago โ†’$576today

Score Overview

1 Year
Scoreโ€”
Net Growth-15.28%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score3.2
Net Growth-171.91%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth382.92%
Rev Trend20%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-6x
Net Trend30%
Net Income Consistency
Rev Growth19x
Rev Trend30%
Revenue Consistency
All Time
Score
Net Growth-6x
Net Trend30%
Net Income Consistency
Rev Growth19x
Rev Trend30%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Spyre Therapeutics Inc. has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. SYRE does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 90.33โ€”
1 Year2025-10-23
$ 22.37303.80%
5 Years2021-10-22
$ 182.50-50.50%
10 Years2016-10-21
$ 156.75-42.37%
All Time2016-04-07
$ 244.25-63.02%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 90M-$ 178M$ 1.14B
2025$ 0.00-$ 155M$ 756M
2024$ 886K-$ 208M$ 603M
2023$ 886K-$ 338M$ 339M
2022$ 2M-$ 83M$ 55M
2021$ 18M-$ 65M$ 93M
2020$ 0.00-$ 80M$ 146M
2019$ 0.00-$ 78M$ 71M
2018$ 3M-$ 44M$ 74M
2017$ 5M-$ 27M$ 50M
IPO2016$ 4M-$ 21M$ 63M
SYRE - Spyre Therapeutics Inc. logo

Spyre Therapeutics Inc. fundamental performance

Between 2020 and 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 80M to -$ 155M. Revenue increased in 1 of those 5 years; net income in 2.

Across Spyre Therapeutics Inc.'s full reported history, from 2016 to 2025, revenue declined from $ 4M to $ 0.00 and net income went from -$ 21M to -$ 155M. Revenue increased in 30% of the years measured; net income in 30%.

Spyre Therapeutics Inc. currently holds a 5-year HDB Score of 3.2 out of 10. How the HDB Score is calculated.

Membership

Explore SYRE with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies